For instance, in TNBC, the combination of nab‐paclitaxel with the anti‐PD‐L1 antibody atezolizumab has demonstrated superior clinical responses compared to the combination of paclitaxel with atezolizumab.[96, 347, 349, 350] In addition, responses to these combination therapies may vary depending on tumor‐specific molecular and immune profiles.[96, 350, 351] Therefore, further research is essential to optimize chemotherapeutic agents and schedules, manage adverse events, and identify predictive biomarkers to guide personalized treatment strategies. This evidence concerns the gene CD274 and neoplasm.